The FDA's recent approval of suzetrigine, marketed as Journavx, represents a major advancement in pain management, being the first new painkiller type in 25 years. This medication, effective for moderate to severe acute pain, competes with opioids by providing similar pain relief without high addiction risks. Suzetrigine works by blocking sodium ion channels, thereby inhibiting pain signals. Clinical trials confirm its effectiveness comparable to opioid-based treatments, coupled with faster action and fewer side effects, marking a pivotal shift in the treatment landscape for pain management.
The FDA has approved suzetrigine for pain relief, marking a significant milestone in pain management by offering an alternative to addictive opioids.
Suzetrigine operates by obstructing sodium ion channels, effectively dampening pain signals before they reach the nervous system.
Collection
[
|
...
]